Geulah Livshits
Stock Analyst at Chardan Capital
(4.31)
# 362
Out of 5,241 analysts
270
Total ratings
47.21%
Success rate
19.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNTI Senti Biosciences Holdings | Maintains: Buy | $11 → $12 | $0.9401 | +1,176.46% | 13 | May 15, 2026 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $17 | $4.71 | +260.93% | 15 | May 11, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 | $3.07 | +258.31% | 24 | May 11, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $16 → $14 | $3.39 | +312.98% | 17 | May 7, 2026 | |
| EDIT Editas Medicine | Maintains: Buy | $3.5 → $4 | $2.53 | +58.10% | 12 | May 5, 2026 | |
| CLYM Climb Bio | Initiates: Buy | $22 | $9.88 | +122.67% | 1 | May 5, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $27 → $30 | $12.69 | +136.41% | 20 | Apr 27, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $210 → $240 | $105.05 | +128.46% | 9 | Mar 31, 2026 | |
| SLDB Solid Biosciences | Maintains: Buy | $15 | $6.51 | +130.41% | 11 | Mar 20, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $12 | $5.45 | +120.39% | 18 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 | $8.37 | +210.82% | 15 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 | $0.783 | +921.71% | 15 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $220 → $323 | $291.75 | +10.71% | 15 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $76 | $48.56 | +56.51% | 17 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 | $10.62 | +135.40% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $4.87 | +310.68% | 15 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $21 | $5.12 | +310.16% | 6 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $2.81 | +220.28% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.27 | +766.14% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.28 | +163.16% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $9.40 | +336.17% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.29 | +264.74% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $48.11 | +332.34% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.18 | +1,255.93% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $5.65 | +1,492.92% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.53 | +13.31% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $19.90 | -9.55% | 1 | Oct 27, 2020 |
Senti Biosciences Holdings
May 15, 2026
Maintains: Buy
Price Target: $11 → $12
Current: $0.9401
Upside: +1,176.46%
Lexeo Therapeutics
May 11, 2026
Maintains: Buy
Price Target: $17
Current: $4.71
Upside: +260.93%
Rocket Pharmaceuticals
May 11, 2026
Maintains: Buy
Price Target: $11
Current: $3.07
Upside: +258.31%
Iovance Biotherapeutics
May 7, 2026
Maintains: Buy
Price Target: $16 → $14
Current: $3.39
Upside: +312.98%
Editas Medicine
May 5, 2026
Maintains: Buy
Price Target: $3.5 → $4
Current: $2.53
Upside: +58.10%
Climb Bio
May 5, 2026
Initiates: Buy
Price Target: $22
Current: $9.88
Upside: +122.67%
Intellia Therapeutics
Apr 27, 2026
Maintains: Buy
Price Target: $27 → $30
Current: $12.69
Upside: +136.41%
Palvella Therapeutics
Mar 31, 2026
Maintains: Buy
Price Target: $210 → $240
Current: $105.05
Upside: +128.46%
Solid Biosciences
Mar 20, 2026
Maintains: Buy
Price Target: $15
Current: $6.51
Upside: +130.41%
Taysha Gene Therapies
Mar 19, 2026
Maintains: Buy
Price Target: $12
Current: $5.45
Upside: +120.39%
Mar 19, 2026
Maintains: Buy
Price Target: $26
Current: $8.37
Upside: +210.82%
Mar 12, 2026
Maintains: Buy
Price Target: $8
Current: $0.783
Upside: +921.71%
Feb 18, 2026
Maintains: Buy
Price Target: $220 → $323
Current: $291.75
Upside: +10.71%
Feb 17, 2026
Maintains: Buy
Price Target: $74 → $76
Current: $48.56
Upside: +56.51%
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $10.62
Upside: +135.40%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.87
Upside: +310.68%
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $5.12
Upside: +310.16%
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $2.81
Upside: +220.28%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.27
Upside: +766.14%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.28
Upside: +163.16%
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $9.40
Upside: +336.17%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $3.29
Upside: +264.74%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $48.11
Upside: +332.34%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.18
Upside: +1,255.93%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $5.65
Upside: +1,492.92%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.53
Upside: +13.31%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $19.90
Upside: -9.55%